Overview
Background
Dr Mollee practices as a consultant haematologist in clinical and laboratory haematology at the Princess Alexandra Hospital and is Associate Professor with the University of Queensland Medical School.
Having trained in Brisbane and Toronto, Dr Mollee has developed an international reputation studying amyloidosis and the plasma cell dyscrasias. He holds appointments with the Medical Scientific Advisory Group of Myeloma Australia, Australian Amyloidosis Network, National Blood Cancer Taskforce and is a member of the AACB Monoclonal Gammopathy Working Group and the International Kidney & Monoclonal Gammopathy Research Group. He is a past Chairman of the Australasian Leukaemia and Lymphoma Group (ALLG) and current Chair of the Australian Amyloidosis Network. He heads the Myeloma Service as well as the Queensland Amyloidosis Centre which runs one of the few clinics in Australia dedicated exclusively to the care of patients with amyloidosis.
Availability
- Associate Professor Peter Mollee is:
- Available for supervision
Qualifications
- Masters (Coursework) of Medical Science, University of Newcastle
- Royal Australasian College of Physicians, Royal Australasian College of Physicians
- Royal College of Pathologists of Australasia, Royal College of Pathologists of Australasia
Research impacts
The research of the Queensland Amyloidosis Centre aims to improved the diagnosis, monitoring and therapy of all types of amyloidosis. The Centre, in collaboration with Pathology Queensland and the Translational Research Institute, developed laser capture macrodisscution and tandem mass spectrometry analysis to accurately diagnosis the type of amyloidosis that patients have and have introuduced this assay into the clinical laboratory. Research to improve the diagnosis and monitoring of this rare disease has also assessed immunoglobulin free light chain assays, bone scintigraphy and novel radionuclide PET tracers. The Queensland Amyloidosis Centre maintains an active clinical trial program in amyloidosis therapies including both investigator-initiated and commercial studies.
Works
Search Professor Peter Mollee’s works on UQ eSpace
2007
Journal Article
Analytical performance of serum free light-chain assay during monitoring of patients with monoclonal light-chain diseases
Tate, Jillian R., Mollee, Peter, Dimeski, Goce, Carter, Andrew C. and Gill, Devinder (2007). Analytical performance of serum free light-chain assay during monitoring of patients with monoclonal light-chain diseases. Clinica Chimica Acta, 376 (1-2), 30-36. doi: 10.1016/j.cca.2006.07.011
2007
Journal Article
Epstein-Barr virus T-cell immunity despite rituximab
Nehring, Angela K., Dua, Ujjwal, Mollee, Peter, Gill, Devinder, Grimmett, Karen, Khanna, Rajiv, Moss, Denis and Gandhi, Maher K. (2007). Epstein-Barr virus T-cell immunity despite rituximab. British Journal of Haematology, 136 (4), 628-632. doi: 10.1111/j.1365-2141.2006.06482.x
2007
Conference Publication
Immunosuppression (IST) can be safely ceased during chemotherapy for PTLD in renal transplant patients
Hourigan, Matthew J., Johnson, David W., Jones, Mark, Gill, Devinder S., Isbel, Nikki, Hawley, Carmel M., Marlton, Paula, Gandhi, Maher, Campbell, Scott B. and Mollee, Peter (2007). Immunosuppression (IST) can be safely ceased during chemotherapy for PTLD in renal transplant patients. American Transplant Congress, San Francisco, CA, USA, 5-9 May 2007. Oxford, England: Wiley-Blackwell. doi: 10.1111/j.1600-6143.2007.01811.x
2007
Conference Publication
Efficacy and safety of sequential treatment with rituximab and CHOP chemotherapy in B-cell PTLD: Results of a prospective international phase II study
Trappe, R., Choquet, S., Oertel, S., LeBlond, V., Ekman, T., Sender, M., Mollee, P, Reinke, P., Lehmkuhl, H., Hummel, M., Jonas, S., Neuhaus, R., Salles, G., Morschhauser, F., Jaccard, A., Anagnostopoulos, I., Raphael, M. and Riess, H. (2007). Efficacy and safety of sequential treatment with rituximab and CHOP chemotherapy in B-cell PTLD: Results of a prospective international phase II study. Annual American Transplant Congress, San Francisco, CA, United States, 5 - 9 May 2007. Malden, MA, United States: Wiley-Blackwell Publishing. doi: 10.1111/j.1600-6143.2007.01811.x
2007
Journal Article
The International Prognostic Index: the “gold-standard” in post-transplant lymphoproliferative disorders after renal transplantation
Hourigan, M. J., Mollee, P. N., Gill, D. S., Doecke, J., Norris, D., Johnson, D. W. and Gandhi, M. K.. (2007). The International Prognostic Index: the “gold-standard” in post-transplant lymphoproliferative disorders after renal transplantation. American Journal of Transplantation, 7, 399-399.
2007
Conference Publication
Immunosuppression (IST) Can Be Safely Ceased during Chemotherapy for PTLD in Renal Transplant Patients
Hourigan, Matthew J., Johnson, David W., Jones, Mark, Gill, Devinder S., Isbel, Nikki, Hawley, Carmel M., Marlton, Paula, Ghandhi, Maher, Campbell, Scott B. and Mollee, Peter (2007). Immunosuppression (IST) Can Be Safely Ceased during Chemotherapy for PTLD in Renal Transplant Patients. American Transplant Congress 2007, USA, 5-9 May 2007. UK: Wiley-Blackwell Publising Ltd.. doi: 10.1111/j.1600-6143.2007.01811.x
2007
Conference Publication
JAK2V617F mutation status predicts thrombotic complications, including arterial thrombosis, in patients with essential thrombocytosis (ET)
Weston, H, Bird, R, Griffiths, V, Jones, M, Grimmett, K, Saal, R, Mills, AK, Gill, D, Marlton, P and Mollee, P (2007). JAK2V617F mutation status predicts thrombotic complications, including arterial thrombosis, in patients with essential thrombocytosis (ET). 49th Annual Meeting of the American-Society-of-Hematology, Atlanta Ga, Dec 08-11, 2007. WASHINGTON: AMER SOC HEMATOLOGY.
2006
Journal Article
Increased Mortality with FLA Compared with ADE Chemotherapy in High-risk AML (Letter to the Editor)
Lane, Steven W., Marlton, Paula and Mollee, Peter N. (2006). Increased Mortality with FLA Compared with ADE Chemotherapy in High-risk AML (Letter to the Editor). Blood, 108 (12), 3950-3951. doi: 10.1182/blood-2006-06-032680
2006
Journal Article
Characterisation and prognostic significance of WT-1 gene expression in acute myeloid leukemia (AML)
Lane, Steven W., Saal, Russell, Negus, Suzanne, Mollee, Peter, Mather, M., Gill, Devinder, Mills, Anthony K., Bird, Robert J., Hourigan, Matthew J., Jones, Mark and Marlton, Paula (2006). Characterisation and prognostic significance of WT-1 gene expression in acute myeloid leukemia (AML). Blood, 108 (11). doi: 10.1182/blood.v108.11.2313.2313
2006
Conference Publication
Prolonged hematologic toxicity from the Hyper-CVAD regimen; manifestations, frequency, and natural history in a cohort of 125 consecutive patients
Gill, Saar, Lane, Steven, Crawford, Julie, Mollee, Peter, Marlton, Paula, Cull, Gavin, Prince, Miles and Seymour, John Francis (2006). Prolonged hematologic toxicity from the Hyper-CVAD regimen; manifestations, frequency, and natural history in a cohort of 125 consecutive patients. 48th Annual Meeting of the American-Society-of-Hematology, Orlando, FL, United States, 9-12 December 2006. Washington, DC, United States: American Society of Hematology. doi: 10.1182/blood.v108.11.2441.2441
2006
Journal Article
Safety and efficacy of pegfilgrastim compared to granulocyte colony stimulating factor (G-CSF)supporting a dose-intensive, rapidly cycling anti-metabolite containing chemotherapy regimen (Hyper-CVAD) for lymphoid malignancy
Lane, Steven W., Crawford, Julie, Kenealy, Melita, Cull, Gavin, Seymour, John F., Prince, H. Miles, Marlton, Paula, Gill, Devinder and Mollee, Peter N. (2006). Safety and efficacy of pegfilgrastim compared to granulocyte colony stimulating factor (G-CSF)supporting a dose-intensive, rapidly cycling anti-metabolite containing chemotherapy regimen (Hyper-CVAD) for lymphoid malignancy. Leukemia and Lymphoma, 47 (9), 1813-1817. doi: 10.1080/10428190600632832
2006
Journal Article
The Hyper-CVAD chemotherapy regimen has an adverse long-term impact on the ability to mobilize peripheral blood stem cells, which can be readily circumvented by using the early cycles for mobilization
Keane, Colm, Gibbs, Simon, Seymour, John F., Mills, Anthony K ., Grimmett, Karen, Van Kuilenberg, Rosita, Russell, Saal, Gill, Devinder, Prince, H. Miles, Marlton, Paula and Mollee, Peter (2006). The Hyper-CVAD chemotherapy regimen has an adverse long-term impact on the ability to mobilize peripheral blood stem cells, which can be readily circumvented by using the early cycles for mobilization. Hematological Oncology, 24 (3), 159-163. doi: 10.1002/hon.784
2006
Journal Article
The effect of the Hyper-CVAD chemotherapy regimen on fertility and ovarian function
Seshadri, T., Hourigan, M. J., Wolf, M., Mollee, P. N. and Seymour, J. F. (2006). The effect of the Hyper-CVAD chemotherapy regimen on fertility and ovarian function. Leukemia Research, 30 (4), 483-485. doi: 10.1016/j.leukres.2005.08.014
2006
Journal Article
A phase II study of thalidomide and vinblastine for palliative patients with Hodgkin's lymphoma
Kuruvilla, John, Song, Kevin, Mollee, Peter, Panzarella, Tony, McCrae, Jan, Nagy, Tracy, Crump, Michael and Keating, Armand (2006). A phase II study of thalidomide and vinblastine for palliative patients with Hodgkin's lymphoma. Hematology, 11 (1), 25-29. doi: 10.1080/10245330500276592
2006
Conference Publication
Real-time quantitative polymerase chain reaction (RQ-PCR) monitoring of minimal residual disease (MRD) in core binding factor acute myeloid leukaemia (CBF AML).
Lane, SW, Saal, R, Mollee, P, Grigg, A, Taylor, K, Seymour, JF, Kennedy, G, Williams, B, Jones, M, Grimmett, K, Griffiths, V, Gill, D, Hourigan, M and Marlton, P (2006). Real-time quantitative polymerase chain reaction (RQ-PCR) monitoring of minimal residual disease (MRD) in core binding factor acute myeloid leukaemia (CBF AML).. 48th Annual Meeting of the American-Society-of-Hematology, Orlando, FL, United States, 9-12 December 2006. Washington, DC, United States: American Society of Hematology.
2006
Journal Article
Hereditary fibrinogen A alpha-chain amyloidosis
Lane, S. W., Goodman, H. J., Francis, L., Bofinger, A. M. and Mollee, P. N. (2006). Hereditary fibrinogen A alpha-chain amyloidosis. Pathology, 38 (4), 380-382. doi: 10.1080/00313020600820823
2006
Journal Article
Plasma Epstein-Barr virus (EBV) DNA is a biomarker for EBV-positive Hodgkin's lymphoma
Gandhi, M. K., Lambley, E., Burrows, J., Dua, U., Elliott, S., Shaw, P. J., Prince, H. M., Wolf, M., Clarke, K., Underhill, C., Mills, T., Mollee, P., Gill, D., Marlton, P., Seymour, J. F. and Khanna, R. (2006). Plasma Epstein-Barr virus (EBV) DNA is a biomarker for EBV-positive Hodgkin's lymphoma. Clinical Cancer Research, 12 (2), 460-464. doi: 10.1158/1078-0432.CCR-05-2008
2006
Conference Publication
Clinical utility and technical pitfalls of the serum free light chain (FLC) assay for monitoring of monoclonal light-chain diseases
Tate, J.R., Mollee, P., Carter, A. and Gill, D. (2006). Clinical utility and technical pitfalls of the serum free light chain (FLC) assay for monitoring of monoclonal light-chain diseases. 58th Annual Meeting of the American Association of Clinical Chemistry, Chicago, IL, United States, 23-27 July 2006. Washington, DC, United States: American Association for Clinical Chemistry.
2006
Conference Publication
Characterisation and prognostic significance of WT-1 gene expression in acute myeloid leukemia (AML).
Lane, SW, Saal, R, Negus, S, Mollee, P, Mather, M, Gill, D, Mills, AK, Bird, RJ, Hourigan, MJ, Jones, M and Marlton, P (2006). Characterisation and prognostic significance of WT-1 gene expression in acute myeloid leukemia (AML).. 48th Annual Meeting of the American-Society-of-Hematology, Orlando Fl, Dec 09-12, 2006. WASHINGTON: AMER SOC HEMATOLOGY.
2006
Journal Article
Effects of hyperlipidemia on plasma sodium, potassium, and chloride measurements by an indirect ion-selective electrode measuring system
Dimeski, Goce, Mollee, Peter and Carter, Andrew (2006). Effects of hyperlipidemia on plasma sodium, potassium, and chloride measurements by an indirect ion-selective electrode measuring system. Clinical Chemistry, 52 (1), 155-156. doi: 10.1373/clinchem.2005.054981
Supervision
Availability
- Associate Professor Peter Mollee is:
- Available for supervision
Before you email them, read our advice on how to contact a supervisor.
Supervision history
Current supervision
-
Master Philosophy
Novel Radionuclide Tracers for Imaging in Amyloidosis
Principal Advisor
Other advisors: Associate Professor Colm Keane
-
Doctor Philosophy
Addressing frailty in older people with haematological malignancies
Associate Advisor
Other advisors: Associate Professor Emily Gordon, Dr Natasha Reid, Professor Ruth Hubbard
Media
Enquiries
For media enquiries about Associate Professor Peter Mollee's areas of expertise, story ideas and help finding experts, contact our Media team: